Cost-Utility Analysis of Routine Anxiety and Depression Screening in Patients Consulting for Osteoarthritis: Results From a Clinical, Randomized Controlled Trial

JESSE KIGOZI, SUE JOWETT, BARBARA I. NICHOLL, MARTYN LEWIS, BERNADETTE BARTLAM, DANIEL GREEN, JOHN BELCHER, KRIS CLARKSON, ZOE LINGARD, CHRISTOPHER POPE, CAROLYN A. CHEW-GRAHAM, PETER CROFT, ELAINE M. HAY, GEORGE PEAT, AND CHRISTIAN D. MALLEN

Objective. To investigate the cost-effectiveness (cost-utility) of introducing general practitioner screening for anxiety and depression in patients consulting for osteoarthritis (OA).

Methods. A cluster-randomized trial-based economic evaluation to assess general practitioners screening for anxiety and depression symptoms in patients consulting for OA compared to usual care (screening for pain intensity) was undertaken over a 12-month period from a UK National Health Service and societal perspective. Patient-level mean costs and mean quality-adjusted life years (QALYs) were estimated, and cost-effectiveness acceptability curves controlling for cluster-level data were constructed. The base-case analysis used the net benefit regressions approach. The 2-stage nonparametric sampling technique was explored in a sensitivity analysis.

Results. The base-case analysis demonstrated that the intervention was as costly as, and less effective than, the control (QALY differential $-0.029$ [95% confidence interval $-0.062, 0.003$]). In the base-case analyses, general practitioner screening for anxiety and depression was unlikely to be a cost-effective option (probability $<5\%$ at £20,000/QALY). Similar results were observed in all sensitivity analyses.

Conclusion. Prompting general practitioners to routinely screen and manage comorbid anxiety and depression in patients presenting with OA is unlikely to be cost-effective. Further research is needed to explore clinically effective and cost-effective models of managing anxiety and depression in patients presenting with clinical OA.

INTRODUCTION

Osteoarthritis (OA) is a common cause of persistent pain, disability, and poor quality of life in older adults. Estimations are that approximately 1 million adults in the UK consult for OA each year (1). OA has negatively impacted the economy of the UK, with direct and indirect costs between 0.25% and 0.50% of gross national product (2,3). Direct costs of OA treatment are driven mainly by total joint arthroplasty, while indirect costs are mostly driven by the loss of productivity due to absenteeism from paid work (4,5). Among other factors, persistent pain and disability-related symptoms have been linked with increased levels of anxiety and depression in patients with OA, who experience
Significance & Innovations

- This is the first economic evaluation assessing general practitioner screening for anxiety and depression in older patients with osteoarthritis (OA) in addition to screening for pain intensity.
- This economic evaluation showed that routine screening for anxiety and depression by general practitioners is unlikely to be cost-effective in patients with OA.
- Further research is needed to explore cost-effective models of managing anxiety and depression in patients presenting with clinical OA.

subsequent worse outcomes (6,7). Patients with OA and associated depression use more medication and are likely to have increased health care resource utilization (8,9). Depression is also a major cause of work-related absenteeism and diminished or reduced productivity (10).

Case finding for depression in primary care has been recommended as a means of improving the identification of depressive symptoms and consequently improving overall quality of life and OA-related pain outcomes (11). Case finding for depression in patients with a chronic physical disease such as OA has been recommended in guidelines by the National Institute for Health and Care Excellence (NICE) (12,13), but these guidelines did not consider the costs and benefits of such strategies. There have been calls to investigate the effectiveness and cost-effectiveness of case finding for anxiety and depression in patients with OA in primary care (14), although to date, evidence of effectiveness and cost-effectiveness remains limited (15–17).

We conducted an economic evaluation alongside a randomized controlled trial (RCT) to establish the cost-effectiveness of introducing general practitioner (GP) screening for anxiety and depression in older patients consulting for OA. The trial and its clinical findings have been reported in full elsewhere (18). Here, we report the cost-effectiveness (cost-utility) analysis, giving specific attention to a comparison of alternative methodologic approaches to analyzing cost-effectiveness data from clinical RCTs.

MATERIALS AND METHODS

Study overview. The economic evaluation took the form of a cost-utility analysis alongside a clinical RCT over a 12-month follow-up period. Randomization was conducted at the GP practice level to prevent contamination between the 2 arms and participating GPs (19). The NHS perspective was adopted in the base-case analysis. Ethical approval for this study was obtained from the Black Country Research Ethics Committee (#11/WM/0093), and all participants gave informed consent to participate in the study. Primary care resource data were obtained from reviewing medical records, while secondary care resource use data were collected via structured patient questionnaires at baseline and at 2 follow-up points, 6 months and 12 months. Because the length of follow-up was 12 months, neither costs nor outcomes were discounted. The primary outcome for clinical effectiveness was patient-reported current pain intensity on a 0–10 numerical rating scale (20), and the primary time point was during 12 months after consultation. Full details of the trial methods and results have been previously published (18).

Interventions. Patients in GP practices implementing the intervention were screened by GPs at point-of-care for anxiety, depression, and current pain intensity with the aid of an electronic template linked with patient records, which appeared following entry of a Read code for an OA-related condition. The template incorporated a 2-item brief depression tool (the Patient Health Questionnaire) (21), and a 2-item ultrabrief anxiety assessment tool (the Generalized Anxiety Disorder instrument) (22). Negative responses to the anxiety and depression questions were used to rule out a potential depression or anxiety diagnosis. The template then prompted GPs to follow NICE clinical guidelines on the management of OA, anxiety, and depression in patients with physical health problems (23–25). The control involved point-of-care current pain intensity assessment prompted by the electronic template, but involving only the item on current pain intensity. We calculated participant-specific costs for the intervention based on information collected within the trial. This calculation was made by asking participating GPs about any additional time they spent screening for anxiety and depression. Intervention costs were then estimated, based on an average 1.29 additional minutes of GP time for screening participants and based on a mean of the summary of responses from the participating GPs in the GP questionnaire survey.

Outcome measures. We used the EuroQol 5-domain instrument 5-level version (EQ-5D-5L), with a value established using the UK value set derived from a UK general population survey (26,27) to estimate quality-adjusted life years (QALYs) gained using the area under the curve approach (28). Imbalances in baseline EQ-5D-5L utility scores were controlled for using a multiple regression–based adjustment (29). This approach allows for estimation of differential QALYs and facilitates prediction of adjusted QALYs, while controlling for baseline utility values. The model included the treatment arm dummy variable and patient-specific baseline utility values (29). The primary outcome for the trial was patient-reported current pain intensity on a 0–10 numerical rating scale (19) across 12 months after consultation. All outcomes were measured at baseline, 3 months, 6 months, and 12 months and were obtained from a self-completed questionnaire administered at these time points.
Resource use and costs. In the base-case analysis, costs were measured from the UK NHS perspective, with overall societal costs considered in the sensitivity analysis. Information about resource use related to OA, anxiety, and depression was collected from general practice records and self-reported questionnaires. Primary care resource use was obtained from a review of medical records covering the full 12-month follow-up period for patients who provided consent, and included primary care contacts and prescribed medications. Patient-level data on primary care consultations (from GP records) at which OA, anxiety, and/or depression were mentioned were noted and recorded by type of consultation and type of professional seen. Secondary care resource use data were collected via self-report postal questionnaires administered at 6 months and 12 months. Secondary care contacts included visits to other health care professionals (e.g., hospital consultants, physiotherapists, counselors, and psychologists), hospital-based investigations (e.g., radiographs, magnetic resonance imaging scans), and procedures (injections, surgeries). Non-NHS health care costs were assessed by obtaining information on a patient’s purchase of over-the-counter medications, treatments, or appliances and their use of private health care using postal self-report questionnaires. Self-reported data on time off from work and occupation were also collected to assess broader economic consequences. Table 1 shows the unit costs and sources used to value health care resources. Unit costs were obtained from the published British National Formulary (30) for estimating the cost of prescribed medication, and from the NHS reference costs (31) and Unit Costs of Health and Social Care (32) for primary and hospital-based resource use items. Productivity costs were estimated using the human capital approach, and salary costs were based on mean weekly earnings by age and sex and UK Standard Occupational Classification coding (33–35). All costs were expressed in 2013/2014 UK prices.

Statistical analysis. We explored the amount of each resource used by patients in each group using frequencies and mean ± SDs. The statistical analysis was conducted on an intent-to-treat basis and in accordance with current RCT guidelines (36). The analysis involved adopting multilevel modeling statistical techniques, taking into consideration clustering in the cost-and-effect data (36,37). The multiple imputation technique using predictive mean matching was used to impute all missing values for the EQ-5D-5L and cost data (38). The imputation model included age, sex, and treatment group, and was based on M = 25 imputed data sets.

Separate generalized equation models, controlling for clustering, were used to estimate the mean incremental costs and QALYs for the intervention relative to the control. Uncertainty was examined by estimating 95% confidence intervals and cost-effectiveness acceptability curves (CEACs), which link the probability of the GP screening intervention being cost-effective to a range of potential threshold values (λ) that the health system may be willing to pay per additional QALY gained (36,39,40). Dependent variables in the multilevel models included costs, QALYs, and net monetary benefits (NMBs), and model coefficient estimates of differences in these variables were used as part of the incremental analysis. Statistical analysis was performed using Stata software, version 12 (41).

Cost-effectiveness analytical approach. In the base-case analysis, CEACs were estimated using an NMB regression approach (42). The NMB method allows costs and outcomes to be considered on the same monetary scale. NMB was defined as \( \lambda \times (\Delta \text{effect}_i) - \Delta \text{cost}_i \), where \( \Delta \text{effect}_i \) is the incremental person-level outcome associated with the screening intervention, \( \Delta \text{cost}_i \) is the additional costs due to screening for anxiety and depression, and \( \lambda \) is willingness to pay per unit of outcome gain. Using the output, we plotted CEACs, showing the likelihood that the screening intervention is cost-effective given different assumptions about willingness to pay for outcomes. The regression analysis adopted methods reflecting the cluster randomized nature of the trial (36,37), by using a regression-based model of net benefits, with general practice as the cluster identifier.

Sensitivity analysis. Sensitivity analyses were performed to assess uncertainty and robustness of the findings. First, CEACs were estimated by using a 2-stage nonparametric bootstrapping technique for comparison purposes (40,43). This approach accounts for clustering between the hierarchical cost-and-effect data. The 2-stage bootstrapping
output from Stata reports the cost-effectiveness probabilities for a range of potential threshold values used to estimate the probability that the intervention was cost-effective. Second, results were presented from a societal perspective, taking into account productivity costs. Third, a complete-case analysis was carried out to assess the impact of missing cost and EQ-5D-5L data.

RESULTS

Overview. Overall, 45 general practices were randomized, 24 to the control group and 20 to the intervention group, with a mean practice list size of 7,397 and 5,850 in the control and intervention groups, respectively. In all, 7,279 patients were identified as eligible, and after appropriate exclusions, 2,042 patients were mailed a postconsultation questionnaire. Individual participants recruited from the intervention and control practices had broadly similar characteristics. A summary of participation rates, by arm and by participant baseline characteristics, is shown in Supplementary Tables 1 and 2, available on the Arthritis Care & Research web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.23568/abstract. A total of 1,412 participants returned questionnaires from 20 intervention practices (n = 501; 35%) and from 24 control practices (n = 911; 65%) and were considered for the base-case analysis.

Complete primary care resource data from GP records were available for 1,235 participants (87%), while complete secondary care resource data were available for 985 participants (70%) who returned questionnaires at both 6 and 12 months. Complete QALY data at baseline, 6 months, and 12 months were available for 573 intervention participants (63%) and 307 control participants (61%). Following the multiple imputation procedure, all 1,412 participants were included in the base-case analysis. The mean age of participants was 65 years, with slightly more women (57%), who were overwhelmingly white (97%), with just over 30% in paid employment.

Resource use. Table 2 shows the disaggregated details of mean resource use for participants with complete resource use data. Service use was summarized under broad categories, and individual items of service use were not imputed. There were minimal differences between the 2 groups in terms of health care use, but the number of GP visits for depression, anxiety, and OA was slightly higher among intervention participants (2.86 versus 2.42), as were visits to other NHS professionals for any reason (0.26 versus 0.13). Similar findings were observed when considering a societal perspective, with the exception of significantly higher reported time off from work in the control group at 12 months (15 days versus 8.3 days).

Health care costs and productivity costs. Table 2 summarizes the mean cost per patient, by group, for each category of cost. All available data are included for each category. Comparing the 2 groups, we found small differences in the costs, with the exception of significant differences in costs from other health care professionals.

Table 2. Health care resource use and costs by trial arm*

| Resource/cost component | Control (n = 633) | Intervention (n = 352) | Control (n = 633) | Intervention (n = 352) |
|-------------------------|------------------|-----------------------|------------------|-----------------------|
| Resource use, units     |                  |                       |                  |                       |
| Primary care†           |                  |                       |                  |                       |
| General practitioner    | 2.42 ± 2.07‡     | 2.86 ± 2.25‡          | 80.92 ± 68.19    | 94.38 ± 73.23         |
| Practice nurse          | 0.03 ± 0.18      | 0.03 ± 0.17           | 0.23 ± 1.57      | 0.27 ± 1.55           |
| Other                   | 0.07 ± 0.34      | 0.04 ± 0.20           | –                | 0.14 ± 1.67           |
| Secondary care appointments§ |            |                       |                  |                       |
| NHS consultant          | 2.07 ± 4.38      | 1.69 ± 2.94           | 134.93 ± 262.94  | 112.45 ± 207.82       |
| Private consultant      | 0.44 ± 1.93      | 0.41 ± 1.70           | 23.48 ± 104.19   | 21.13 ± 80.89         |
| Other professionals, NHS hospitals | 0.13 ± 0.53‡ | 0.26 ± 1.24‡          | 10.58 ± 36.41    | 17.48 ± 48.47         |
| Other professionals, private hospitals | 0.06 ± 0.56 | 0.05 ± 0.50           | 0.07 ± 1.74      | 0.25 ± 3.31           |
| Investigations and treatments§ | 372 (58.8)% | 197 (55.9)%           | 377.21 ± 1,153.01| 353.33 ± 1,014.55     |
| Prescriptions           |                  |                       |                  |                       |
| Anti-anxiety/anti-depression drugs, no. (%) | 150 (19) | 100 (23) | – | – |
| OA drugs, no. (%)       | 567 (71)         | 343 (78)              | –                | –                     |
| Prescribed medication   | –                | –                     | 225.49 ± 205.80  | 225.59 ± 190.22       |
| Over-the-counter medicines/treatments§ | 373 (58.9)% | 201 (57.10)%          | 13.55 ± 50.29    | 14.10 ± 58.46         |
| Productivity loss/costs# | 15.01 ± 31.96  | 8.34 ± 16.95          | 1,094.87 ± 2,530.32| 644.25 ± 1,460.85    |
| Productivity costs**    | –                | –                     | 310.74 ± 1,441.57| 174.59 ± 816.72       |

* Values are the mean ± SD per patient, by treatment group, for patients providing health care utilization data, unless indicated otherwise.
† Data based on medical records review of available data and include anxiety/depression and OA-related health care use.
‡ Significant differences between the groups, because the value zero is not contained in the 95% confidence interval. Confidence intervals for mean differences in resource use were obtained by bias-corrected and accelerated nonparametric bootstrapping, using 1,000 replications.
§ Data based on self-reported questionnaires at 6 and 12 months and include secondary health care use for any health reason.
¶ Number (%) of participants reporting usage are given instead of mean.
# Indirect costs based on the subsample of respondents in paid employment at 12 months (n = 280).
** Indirect costs based on the complete-case data set (n = 985).
such as occupational therapists, acupuncturists, and chiropractors) and from productivity loss. NHS, health care, and societal costs were similar in both groups, although slightly higher in the control arm. Adjusting for clustering in costs resulted in negligible differences between the groups.

At 12 months of follow-up, 98 in the intervention group (26.4%) and 182 in the control group (28.2%) were in paid employment. Of those reporting being employed, 75 patients (11.6%) in the intervention group reported time off from paid work compared with 35 (9.4%) in the control group. Over a period of 12 months of follow-up, the mean days taken off from work was higher in the control arm (15.0 days) than the intervention arm (8.3 days), and this difference translated to higher productivity costs in the control arm compared to the intervention arm (Table 2).

### Health outcomes and estimation of cost-effectiveness.

The results for analysis of the health outcome measures (mean EQ-5D-5L scores and QALYs) are shown in Table 3. In terms of QALYs gained at 12 months, the mean estimates were 0.686 for the screening intervention and 0.711 for the control, showing higher QALY scores for the control group after adjusting for baseline differences. A similar result was observed in the unadjusted QALY scores.

### Estimation of cost effectiveness.

Estimates showed that the intervention was associated with lower QALYs and that the adjusted difference in cost between the 2 groups was minimal (£1.02 lower in the intervention arm). The mean cost and outcome results of the cost-utility analysis based on the net monetary benefit approach and forming the base-case analysis are shown in Tables 3 and 4. The findings indicate that there is a very low probability (<10%) of the intervention being cost-effective at conventional willingness-to-pay thresholds for additional QALYs (£20,000 to £30,000 per QALY).

### Sensitivity analysis results.

Similar results were observed when using the 2-stage nonparametric bootstrap approach. The probability of the intervention being cost-effective remained low (<10%) at a conventional willingness-to-pay threshold for additional QALYs (£20,000 to £30,000 per QALY). Figure 1 shows the probability that the screening intervention would be seen as cost-effective using a CEAC for different values of willingness to pay from an NHS and societal perspective–based net monetary benefit approach.

### Table 3. Cost-utility analysis using the net benefit regression approach*

|                   | Control (n = 911) | Intervention (n = 501) | Incremental analysis, intervention vs. control, mean differences (95% CI)† |
|-------------------|-------------------|------------------------|--------------------------------------------------------------------------|
| **Cost analysis**, £ |                   |                        |                                                                          |
| NHS cost          | 759.74 ± 1152.38  | 744.09 ± 1008.36       | 1.02 (−135.96, 138.02)                                                   |
| Health care cost   | 794.73 ± 1163.13  | 777.75 ± 1031.82       | 2.70 (−138.28, 143.69)                                                   |
| Societal cost      | 1071.69 ± 1866.80 | 946.34 ± 1351.82       | −122.29 (−318.50, 73.91)                                                |
| **Effectiveness analysis** |                |                        |                                                                          |
| Unadjusted QALYs gained | 0.715 ± 0.216    | 0.679 ± 0.220          | −0.029 (−0.062, 0.003)§                                                 |
| Adjusted QALYs gained | 0.711           | 0.686                  |                                                                          |

* Values are the mean ± SD unless indicated otherwise. Data set is imputed. 95% CI = 95% confidence interval; QALY = quality-adjusted life year. † Mean differences adjusted for clustering in cost and QALY outcomes. § \( P = 0.072 \).

### Table 4. Cost-effectiveness analysis using the net benefit regression approach, with probability that treatment is cost effective at \( \lambda \)*

| Threshold value estimate | NHS | Societal |
|--------------------------|-----|----------|
| \( \lambda = £0 \)       | 51  | 89       |
| \( \lambda = £5,000 \)   | 4   | 36       |
| \( \lambda = £10,000 \)  | 3   | 16       |
| \( \lambda = £15,000 \)  | 3   | 10       |
| \( \lambda = £20,000 \)  | 3   | 8        |
| \( \lambda = £25,000 \)  | 3   | 7        |
| \( \lambda = £30,000 \)  | 3   | 6        |
| \( \lambda = £35,000 \)  | 3   | 6        |
| \( \lambda = £40,000 \)  | 3   | 5        |

* Values are the percentage. Data set is imputed. \( \lambda \) = willingness to pay per unit of outcome gain.

### Figure 1.

Cost-effectiveness acceptability curve for the comparison of case finding versus pain only based on the net monetary benefit regression approach. QALYs = quality-adjusted life years.
Recall (46,47). A further strength is that the use of the QALY report data is that respondents could potentially underreport resource use data. However, a limitation of only using self-reported data is that the study reports comprehensive data, including information outside the main NHS perspective in OA patients is unlikely to be a cost-effective option, similar results are observed regardless of the perspective or approach adopted for the economic analysis. There was minimal difference between the 2 groups in terms of costs, and the finding that additional screening for anxiety and depression is unlikely to be cost-effective is primarily based on the evidence that shows slightly higher QALYs in the control group. The results supplement the main trial findings that found a small significant difference in the direction of worse pain outcomes among those screened for depression and anxiety compared to those not screened (18). Further exploration of these results using probability bias analysis suggests the results could plausibly be attributed to selection bias (44). In both analytical approaches considered, probability of GP screening for anxiety and depression being cost-effective remained low (<30%) at the recommended NICE thresholds of £20,000 to £30,000 (45). This is the first economic evaluation assessing GP screening for anxiety and depression in older people with OA in addition to screening for pain intensity. The study was based on a large sample of a wide range of patients with clinically diagnosed OA (n = 1,412) across a number of locations (45 practices). Resource use information was collected using a combination of GP records and self-reported data, including information outside the main NHS perspective, and therefore the study reports comprehensive resource use data. However, a limitation of only using self-report data is that respondents could potentially underreport resource utilization, particularly over longer periods of recall (46,47). A further strength is that the use of the QALY measure in the cost-effectiveness analysis may have captured a broader range of effects of screening than the pain measure used in the clinical article, given that the EQ-5D-5L used to generate the QALY measure includes dimensions of pain, mobility, anxiety, and depression. In addition, the analysis used a pragmatic and rigorous study design and employed comparative statistical methods for analyzing cost-effectiveness data alongside cluster trials, based on recommended methods (36,48).

However, there are also some limitations. The amount of missing data in the primary care and secondary care data requiring imputation may be of concern. Response rates for the secondary care costs (70% at 12 months) and QALYs (62% over 12 months) were relatively low. Multiple imputation using predictive mean matching was used to address potential biases resulting from incomplete data. However, a limitation of this approach is that it does not take into consideration the multilevel structure of the data. Moreover, the imputation model specified could have included a wider set of variables and covariates. Results of the base-case (imputed) and complete-case analysis were comparable in regard to policy implications.

Evidence supporting the effectiveness of screening for anxiety and depression in patients with OA remains limited and with contradictory findings (14,18,49). No previous studies have assessed the cost-effectiveness of GP screening for anxiety and depression in addition to screening for pain intensity in patients with OA at risk of depression. Our study, in line with findings from a previous review (16), suggests that screening for anxiety and depression in general is unlikely to be a cost-effective option.

Few studies have attempted to compare alternative methods for the economic analysis of clinical RCTs (48), although methodologic guidance on the use of these methods to analyze data from clinical RCTs has been established. The analysis reported in this article showed similar findings from the different approaches explored (net monetary benefit approach and 2-stage bootstrap sampling process). The results obtained here may not be generalizable to another disease or context. Further empirical studies exploring alternative methods of analyzing clinical RCTs in other disease areas or contexts are needed.

Our results show that patients receiving a screening intervention for depression, anxiety, and pain intensity were associated with higher primary care costs, but lower hospital and productivity loss costs. However, patients receiving the screening intervention were associated with slightly lower quality of life outcomes. The economic evaluation demonstrated that adding routine screening for anxiety and depression compared to usual care is not a cost-effective option for patients with OA. The study has broader implications in depression case finding interventions targeted at patients with OA, particularly with the assumption that such services are money-saving to the NHS and improve overall OA-related health outcomes. Here, productivity and hospital cost savings were observed, but the probability of overall cost-effectiveness was judged very low at recommended incremental cost-effectiveness ratio thresholds.

Nonetheless, given the significant costs associated with OA and the increased risks of anxiety and depression in this group of patients, future research should explore the...
costs and benefits of appropriate management strategies for anxiety and/or depression once detected in patients presenting with clinical OA in primary care. Assessing ways of identifying those anxiety or depressive symptoms that are likely to make future management services both less cost-effective and more costly would also be helpful.

ACKNOWLEDGMENTS

The authors thank Keele Clinical Trials Unit (Keele University, UK) for their support. We also thank all participating patients and general practices.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication. Dr. Jowett had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Nicholl, Bartlam, Green, Belcher, Pope, Chew-Graham, Croft, Hay, Peat, Mallen.

Acquisition of data. Kigozi, Jowett, Lewis, Clarkson, Lingard.

Analysis and interpretation of data. Kigozi, Jovett, Lewis, Mallen.

REFERENCES

1. Arthritis Research UK. Osteoarthritis: an information booklet. Chesterfield: Arthritis Research UK; 2004.
2. Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of osteoarthritis: a systematic review of cost-of-illness studies. Semin Arthritis Rheum 2015;44:531–41.
3. Xie F, Kovic B, Jin X, He X, Wang M, Silvestre C. Economic and humanitarian burden of osteoarthritis: a systematic review of large sample studies. Pharmacoeconomics 2016;34:1087–100.
4. Chen A, Gupte A, Akhtar K, Smith K, Cobb J. The global economic cost of osteoarthritis: how the UK compares. Arthritis 2012. URL: https://doi.org/10.1155/2012/698709.
5. Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Luisa Brandi M, et al. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Rheumatology and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2013;43:303–13.
6. Buszewicz MJ, Chew-Graham C. Improving the detection and management of anxiety disorders in primary care. Br J Gen Pract 2011;61:489–90.
7. Sharma A, Kudesia P, Shi Q, Gandhi R. Anxiety and depression in patients with osteoarthritis: impact and management challenges. Open Access Rheumatol 2016;8:103–13.
8. Rosemann T, Gensichen J, Sauer N, Laux G, Szecsenyi J. The impact of comorbid depression on quality of life and health service utilisation in patients with osteoarthritis. Rheumatology Int 2007;27:859–63.
9. Yohannes MA, Caton S. Management of depression in older people with osteoarthritis: a systematic review. Aging Ment Health 2010;14(6):637–51.
10. Evans-Lacko S, Knapp M. Global patterns of workplace productivity for people with depression: absenceeeism and presenteeism across eight diverse countries. Soc Psychiatry Psychiatr Epidemiol 2016;51:1525–37.
11. Lin EH, Tang L, Katon W, Hegel MT, Sullivan MD, Unutzer J. Arthritis pain and disability: response to collaborative depression care. Gen Hosp Psychiatry 2006;28:482–8.
12. National Institute for Health and Clinical Excellence. The care and management of osteoarthritis in adults. 2008. Clinical guideline (CG59).
13. National Institute for Health and Clinical Excellence. Depression in adults with a chronic physical health problem: recognition and management. 2009. Clinical guideline (CG91).
14. Gilbody S, Sheldon T, House A. Screening and case-finding instruments for depression: a meta-analysis. CMAJ 2008;178:997–1003.
15. Roy-Byrne P, Sullivan MD, Sherbourne CD, Golinelli D, Craske MG, Sullivan G, et al. Effects of pain and prescription opioid use on outcomes in a collaborative care intervention for anxiety. Clin J Pain 2013;29:800–6.
16. Thombs BD, Roseman M, Coyne JC, de Jonge P, Delisie VC, Arthurs E, et al. Does evidence support the American Heart Association’s recommendation to screen patients for depression in cardiovascular care? An updated systematic review. PLoS ONE 2013;8:e52654.
17. Thombs BD, Ziegelstein RC, Roseman M, Kloda LA, Ioannidis JP. There are no randomized controlled trials that support the United States Preventive Services Task Force Guideline on screening for depression in primary care: a systematic review. BMC Med 2014;12:13.
18. Mallen CD, Nicholl BI, Lewis M, Bartlam B, Green D, Jowett S, et al. The effects of implementing a point-of-care electronic template to prompt routine anxiety and depression screening in patients consulting for osteoarthritis (the Primary Care Osteoarthritis Trial): a cluster randomised trial in primary care. PLoS Med 2017;14:e1002273.
19. Torgerson David J. Contamination in trials: is cluster randomisation the answer? BMJ 2001;322:355–7.
20. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain 1992;50:133–49.
21. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression: two questions are as good as many. J Gen Intern Med 1997;12:439–45.
22. Kroenke K, Spitzer RL, Williams JB, Menahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:317–25.
23. National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical guideline for care and management in adults. London: Royal College of Physicians; 2008. Report CG59.
24. National Institute for Health and Care Excellence. The British Psychological Society and The Royal College of Psychiatrists. Depression in adults with a chronic physical health problem: recognition and management. 2009. Clinical guideline (CG91).
25. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. 2011. Clinical guideline (CG113).
26. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.
27. Devlin N, Shah K, Feng Y, Mulheron B, Van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ 2018;27:7–22.
28. Morris S, Devlin N, Parkin D. Economic analysis in health care. Chichester (UK): John Wiley; 2007.
29. Manca A, Hawkins N, Sculpher J. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96.
30. British Medical Association Royal Pharmaceutical Society of Great Britain. British national formulary. 66th ed. London: BMJ Books; 2013.
31. Department of Health. NHS reference costs 2012 to 2013. URL: https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013.
32. Personal Social Services Research Unit. Unit costs of health and social care. 2013. URL: http://www.pssru.ac.uk/project-pages/unit-costs/2013/.
33. Office of National Statistics. Standard occupational classification. SOC. 2010. URL: https://www.ons.gov.uk/methodology/classificationsandstandards/standardoccupationalclassification/socc2010.
34. Office for National Statistics. Annual survey of hours and earnings. URL: http://www.ons.gov.uk. 2013.
35. Knies S, Severens JL, Ament AJ, Evers SM. The transferability of valuing lost productivity across jurisdictions: differences between national pharmacoeconomic guidelines. Value Health 2010;13:519–27.
36. Gomes M, Ng ES, Grieve R, Nixon R, Carpenter J, Thompson SG. Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials. Med Decis Making 2012;32:350–61.
37. Ng ES, Diaz-Ordaz K, Grieve R, Nixon RM, Thompson SG, Carpenter JR. Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: an approach to model choice. Stat Methods Med Res 2016;25:2036–52.
38. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3–15.
39. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002;11:415–30.
40. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106–8.
41. StataCorp. Stata statistical software: Release 11. 2009.
42. Glick H. Economic evaluation in clinical trials. Oxford (UK): Oxford University Press; 2007.
43. Ng ES, Grieve R, Carpenter J. Two-stage non-parametric bootstrap sampling with shrinkage correction for clustered data. Stat J 2013;13:141–64.
44. Barnett LA, Lewis M, Mallen CD, Peat G. Applying quantitative bias analysis to estimate the plausible effects of selection bias in a cluster randomised controlled trial: secondary analysis of the Primary care Osteoarthritis Screening Trial (POST). Trials 2017;18:585.
45. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008;26:733–44.
46. Petrou S, Murray L, Cooper P, Davidson LL. The accuracy of self-reported healthcare resource utilization in health economic studies. Int J Technol Assess Health Care 2002;18:705–10.
47. Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. Med Care Res Rev 2006;63:217–35.
48. Bachman MO, Fairall L, Clark A, Mugford M. Methods for analysing cost-effectiveness data from cluster randomised trials. Cost Eff Resour Alloc 2007;5:12.
49. Hickie IB, Davenport TA, Ricci CS. Screening for depression in general practice and related medical settings. Med J Aust 2002;177:S111–6.